BioMark Diagnostics (BUX) AI Stock Analysis

• Market Cap: C$64.11M
• Dividend Yield: N/A
• Average Volume (3M): 16.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.14
• Revenue Growth: -21.89%
• EPS Growth: 26.36%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 105,090,210
• 10 Day Avg. Volume: 19,330
• 30 Day Avg. Volume: 16,464
• PEG Ratio: 0.71
• Price to Book (P/B): -41.95
• Price to Sales (P/S): 156.67
• P/FCF Ratio: -25.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: C$0.61 ▲(33.48% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is held back primarily by weak financial performance (minimal/declining revenue, large losses, and significant negative free cash flow with elevated financing risk). Technicals provide partial support due to a clear uptrend and positive MACD, but momentum appears somewhat stretched. Valuation is constrained by a negative P/E and no dividend data.

Positive Factors

Focused diagnostics R&D

A clear strategy centered on blood-based cancer diagnostics aligns with durable structural demand for earlier, less-invasive detection and ongoing disease monitoring. Clinical validation cycles and biomarker IP can produce long-lived commercial opportunities and higher barriers to entry if assays succeed.

Moderate reported leverage

On the latest TTM snapshot debt is modest relative to equity, implying interest and principal obligations are not presently overwhelming. This affords management more runway and optionality to invest in trials or commercialization versus a highly leveraged peer, supporting operational flexibility over months.

Evidence of cash flow improvement

An improving free-cash-flow trend, even from a negative base, suggests operating efficiencies or revenue progress. If sustained, that trend reduces near-term financing needs and indicates management can narrow cash burn, improving the firm’s ability to execute clinical and commercialization milestones over the next several months.

Negative Factors

Minimal and declining revenue

Revenue is very small and fell materially year-over-year, indicating weak commercialization traction. Persistently low sales undermine scalability, make covering fixed R&D and SG&A difficult, and extend reliance on financing until assays achieve market adoption or meaningful contract wins.

Material negative free cash flow

Sustained negative free cash flow on the order of millions requires repeated external funding, increasing dilution or refinancing risk. Over a multi-month horizon this reduces strategic flexibility, pressures milestone execution, and elevates the probability management must prioritize cash conservation over growth investments.

Deep, persistent losses

Profitability is severely negative, reflecting high operating costs relative to tiny sales. Continued losses constrain reinvestment, make it harder to achieve scale economics, and extend dependence on capital markets — a structural impediment to becoming self-sustaining within the medium term.

BioMark Diagnostics Business Overview & Revenue Model

Company Description

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

How the Company Makes Money

BioMark Diagnostics generates revenue through the commercialization of its diagnostic tests and related services. The company primarily earns money by selling its proprietary test kits to hospitals, laboratories, and healthcare professionals, who utilize these products to enhance cancer detection capabilities. Additionally, BioMark may engage in partnerships with pharmaceutical companies and research institutions for collaborative studies, which can provide funding and shared resources. These partnerships, along with potential licensing agreements for their technology, contribute significantly to their revenue streams. Furthermore, the company may explore reimbursement agreements with insurance providers to ensure coverage for their diagnostic tests, thereby expanding their market reach and increasing sales.

BioMark Diagnostics Financial Statement Overview

Summary

Early-stage profile with very small and declining TTM revenue (~92K, ~-26% vs prior), deeply negative profitability (net margin roughly -13x revenue) and material ongoing cash burn (TTM free cash flow about -2.1M). Balance sheet leverage is not extreme currently, but historical volatility including periods of negative equity raises financing/dilution risk.

Income Statement

The business remains in a very early/revenue-light phase with persistent, sizable losses. TTM (Trailing-Twelve-Months) revenue is modest (about 92K) and down sharply versus the prior period (roughly -26%), while profitability is deeply negative (TTM net margin around -13x revenue and EBITDA also materially negative). There is some historical revenue improvement versus earlier years, but the overall trajectory is still dominated by high operating costs relative to sales and volatile gross profit.

Balance Sheet

Leverage looks moderate on the latest TTM snapshot (debt roughly 712K versus equity about 508K), suggesting debt is not currently overwhelming. However, the balance sheet has shown meaningful volatility over time, including periods of negative equity in prior annual reports, which raises risk around funding needs and financial stability. Returns to shareholders are also negative in TTM (driven by net losses), indicating the balance sheet is not yet supporting profitable scale.

Cash Flow

Cash generation remains the key weakness: operating cash flow is negative across all periods, and TTM (Trailing-Twelve-Months) free cash flow is meaningfully negative (about -2.1M), implying continued cash burn. While free cash flow showed an improvement rate in the latest TTM data, the company is still consuming cash and appears reliant on external financing until revenues scale and losses narrow.

Breakdown	TTM	Jun 2024	Jun 2022	Jun 2021	Mar 2021	Mar 2020
Income Statement
Total Revenue	91.77K	154.22K	153.49K	43.93K	0.00	263.28K
Gross Profit	-135.75K	154.22K	-232.70K	43.93K	-13.69K	263.28K
EBITDA	-1.29M	-1.46M	-1.35M	-1.22M	-1.08M	-1.20M
Net Income	-1.70M	-1.93M	-1.84M	-1.45M	-1.09M	-1.22M
Balance Sheet
Total Assets	2.14M	3.13M	732.29K	1.47M	952.94K	637.29K
Cash, Cash Equivalents and Short-Term Investments	1.29M	2.48M	72.04K	382.71K	877.68K	611.80K
Total Debt	711.78K	454.16K	823.87K	1.05M	119.32K	8.66K
Total Liabilities	1.63M	1.39M	1.88M	2.11M	1.03M	1.08M
Stockholders Equity	508.03K	1.74M	-1.15M	-635.69K	-79.09K	-439.13K
Cash Flow
Free Cash Flow	-2.05M	-1.10M	-919.72K	-1.26M	-455.55K	-454.57K
Operating Cash Flow	-1.42M	-1.09M	-914.42K	-1.20M	-455.55K	-453.79K
Investing Cash Flow	-1.43M	-3.53K	-5.30K	-59.20K	-3.20K	-790.00
Financing Cash Flow	3.25M	3.42M	609.05K	768.16K	724.63K	1.05M

BioMark Diagnostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.46
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BUX, the sentiment is Positive. The current price of 0.46 is below the 20-day moving average (MA) of 0.55, below the 50-day MA of 0.51, and above the 200-day MA of 0.39, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 66.92 is Neutral, neither overbought nor oversold. The STOCH value of 85.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BUX.

BioMark Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BUX	48 Neutral	C$64.11M	-32.47	―	―	-21.89%	26.36%
EDT	45 Neutral	$384.72M	-3.46	―	―	34.85%	-62.50%
TELO	43 Neutral	C$4.52M	-2.38	-9999.00%	―	―	19.05%
SONA	41 Neutral	C$40.68M	-21.43	-2846.90%	―	―	10.97%

BioMark Diagnostics Corporate Events

BioMark Wins Peer-Reviewed Validation for AI-Driven Lung Cancer Detection Model

BioMark Diagnostics has achieved a key validation milestone with the acceptance of its machine learning-driven lung cancer detection research for publication in the peer-reviewed journal Frontiers in Oncology. Developed in collaboration with Harrisburg University of Science and Technology, the study demonstrates that leveraging pathway-based plasma metabolomic biomarkers and interpretability tools such as SHAP analysis can enhance diagnostic accuracy and deepen understanding of the metabolic mechanisms underlying early-stage lung cancer. The publication provides third-party confirmation of BioMark’s long-term investment in AI infrastructure and metabolomic pathway analysis, strengthening its credibility at a time when investors and the healthcare industry are demanding robust proof of concept for AI-enabled medical technologies and reinforcing its positioning at the intersection of oncology, metabolomics and advanced data science.

The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.45 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.

BioMark Wins Peer-Reviewed Validation for AI-Driven Lung Cancer Detection Model

BioMark Diagnostics has achieved a key validation milestone with the acceptance of its machine learning-driven lung cancer detection research for publication in the peer-reviewed journal Frontiers in Oncology. Developed in collaboration with Harrisburg University of Science and Technology, the study demonstrates that leveraging pathway-based plasma metabolomic biomarkers and interpretability tools such as SHAP analysis can enhance diagnostic accuracy and deepen understanding of the metabolic mechanisms underlying early-stage lung cancer. The publication provides third-party confirmation of BioMark’s long-term investment in AI infrastructure and metabolomic pathway analysis, strengthening its credibility at a time when investors and the healthcare industry are demanding robust proof of concept for AI-enabled medical technologies and reinforcing its positioning at the intersection of oncology, metabolomics and advanced data science.

The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.45 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.

BioMark Leverages Landmark Lung Cancer Studies and New Funding to Drive 2026 Expansion

BioMark Diagnostics reported a transformative 2025 marked by major capacity expansion, clinical validation and growing industry recognition, as it doubled laboratory throughput, bolstered its technical team, advanced AI/ML capabilities, and completed Canada’s largest lung cancer diagnostic study involving more than 7,000 patients. The company was selected as the exclusive partner for the 10,000-patient HANSE lung cancer trial, submitted ISO 15189 documentation to support future U.S. CLIA/CAP accreditation, secured over $4.5 million in capital plus multiple government and foundation grants, and gained visibility through peer-reviewed publications and awards, collectively strengthening its commercialization prospects, international expansion, and appeal to both traditional and impact-focused investors ahead of key 2026 milestones in regulatory approvals, lab services launch and strategic partnerships.

The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.49 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.

BioMark Adds AI-Focused Investor James Lavender to Board to Drive U.S. Expansion

BioMark Diagnostics has appointed technology investor and AI-focused growth strategist James Lavender to its board of directors following approval at the company’s recent annual general meeting. Lavender, a major participant in BioMark’s March 2025 financing round, has been closely involved in advancing the company’s U.S. market entry, helping to establish connections with state-level bodies and strategic investment groups, while also championing broader use of artificial intelligence and machine learning to scale BioMark’s metabolomics-based oncology diagnostics. Management expects his software, enterprise sales and U.S. market development experience to support the company’s transition from development to commercial execution, strengthen its commercialization roadmap, and accelerate the expansion of its lab services footprint in the United States.

The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.49 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.

BioMark Launches ISO 15189 Accreditation Drive to Accelerate Global Commercialization

BioMark Diagnostics Inc. has begun the process to obtain ISO 15189 accreditation for its medical laboratory in Quebec City through the Standards Council of Canada, with the accreditation program officially launched on December 19, 2025 and a site visit expected in early 2026. The move represents a key step in the company’s shift from an R&D-focused operation to a commercial-stage diagnostic business, as ISO 15189 is expected to facilitate access to global markets, support strategic partnerships and licensing deals, and reassure hospitals, biopharma partners and payors about the quality and reliability of its mass spectrometry-based liquid biopsy assays. Following ISO 15189, BioMark plans to pursue CLIA and CAP accreditations to serve the U.S. cancer diagnostics market with its laboratory-developed tests, underscoring its broader commercialization and international expansion strategy.

The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.49 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.